Meanwhile, our fabricated A6 peptide functionalized nanoparticles with CD44 and Hsp90 targets display a broad anti-cancer spectrum both in CD44 positive hematological malignancies and solid tumors, which are rarely reported in one nanomedicine, and it is a promising strategy to therapy hematological malignancies and solid tumors. This evidence concerns the gene CD44 and cancer.